Company Overview and News
TORONTO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Aguia Resources Limited (ASX: AGR, TSXV:AGRL) (“Aguia” or the “Company”) is pleased to confirm that a 3,000 metre diamond drilling program at the Big Ranch copper prospect in Southern Brazil is now underway.
AGR MALRY MALRF MIN
TORONTO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Aguia Resources Limited (ASX: AGR, TSXV:AGRL) (“Aguia” or “Company”) has retained Questrade, Inc. (“Questrade”) to provide market maintenance services to the Company in compliance with regulatory guidelines. Questrade will trade shares of the Company on the TSX Venture Exchange for the purposes of maintaining a reasonable market and improving the liquidity of the Company’s common shares.
TORONTO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Aguia Resources Limited (ASX: AGR, TSXV: AGRL) (“Aguia” or “Company”) is pleased to report that further sampling along the Big Ranch target has returned 13.14 grams per tonne gold (g/t Au) in a gossan sample, one of 17 gossan samples reported below (Table 1). As announced previously, the Company has discovered a new zone of copper mineralisation on ground staked within the Rio Grande Copper Belt, as a result of ongoing regional exploration activities in the State of Rio Grande do Sul, Brazil.
TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Aguia Resources Limited (“Aguia” or the “Company”) (TSX VENTURE:AGRL) (ASX:AGR) announced today that it has concluded a bought deal private placement financing of 14,285,800 units of the Company (the “Units”) at a price of CAD$0.35 per Unit for gross proceeds of approximately CAD$5.0 million (the “Offering”).
Aguia Resources Limited (“Aguia” or the “Company”) (TSXV:AGRL) (ASX:AGR) announces that following the release of the results of a Bankable Feasibility Study on March 20, 2018, an updated NI 43-101 Compliant Technical Report for the Três Estradas Phosphate Project has been prepared and filed with the Canadian regulatory authorities.
* AGUIA RESOURCES LTD - ENTERED INTO BOUGHT DEAL PRIVATE PLACEMENT FINANCING AGREEMENT TO SELL 14.3 MILLION UNITS AT CAD$0.35 PER UNIT
TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- Aguia Resources Limited (“Aguia” or the “Company”) (TSX VENTURE:AGRL) (ASX:AGR) announced today that it has entered into a bought deal private placement financing agreement to sell 14,285,800 units of the Company (the “Units”) at a price of CAD$0.35 per Unit for gross proceeds of approximately CAD$5.0 million (the “Offering”).
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:AGR / AGUIA RESOURCES LIMITED on message board site Silicon Investor.